Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cempra nets $94mm via FOPO

Executive Summary

Antibiotics developer Cempra Inc. netted $94mm through a follow-on offering of 4.17mm common shares at $24 each. Some of the proceeds will support the US launch of solithromycin for community-acquired bacterial pneumonia once the drug gets FDA approval. Additional funds will help additional development of solithromycin for gonorrhea, and Taksta for acute bacterial skin and skin structure infections and refractory bone and joint infections.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies